Gentamicin Exposure and Sensorineural Hearing Loss in Preterm Infants.
Gentamicin Exposure and Sensorineural Hearing Loss in Preterm Infants.
复制标题
DOI：
10.1371/journal.pone.0158806
复制
发表时间：
2016
期刊：
影响因子：
3.7
通讯作者：
Giannoni E
中科院分区：
文献类型：
--
作者：
Fuchs A;Zimmermann L;Bickle Graz M;Cherpillod J;Tolsa JF;Buclin T;Giannoni E
评估庆大霉素暴露对极低出生体重儿（VLBW）感音神经性听力损失（SNHL）的影响。在1993年至2010年间出生、胎龄< 32周和/或出生体重< 1500 g、出生后5年内出现SNHL的婴儿中，确定了庆大霉素暴露情况。对于每个病例，我们选择了两个匹配性别、胎龄、出生体重和出生年份的对照。我们确定了25名受SNHL影响的婴儿，导致我们的VLBW婴儿群体中SNHL的发病率为1.58%。研究组接受庆大霉素治疗的婴儿比例为76%，对照组为70% （p = 0.78）。给药的庆大霉素总累积剂量在研究组（中位数10.2 mg/kg, Q1-Q3 1.6-13.2）和对照组（中位数7.9 mg/kg, Q1-Q3 0-12.8, p = 0.47）之间没有差异。研究组和对照组庆大霉素治疗的中位持续时间均为3天（p = 0.58）。庆大霉素最大预测谷血清水平、曲线下累积面积和庆大霉素清除率在病例和对照组之间无差异。庆大霉素对SNHL的影响可以通过短期治疗、监测血液水平和调整剂量来最小化。
To evaluate the impact of gentamicin exposure on sensorineural hearing loss (SNHL) in very low birth weight (VLBW) infants. Exposure to gentamicin was determined in infants born between 1993 and 2010 at a gestational age < 32 weeks and/or with a birthweight < 1500 g, who presented with SNHL during the first 5 years of life. For each case, we selected two controls matched for gender, gestational age, birthweight, and year of birth. We identified 25 infants affected by SNHL, leading to an incidence of SNHL of 1.58% in our population of VLBW infants. The proportion of infants treated with gentamicin was 76% in the study group and 70% in controls (p = 0.78). The total cumulated dose of gentamicin administered did not differ between the study group (median 10.2 mg/kg, Q1-Q3 1.6–13.2) and the control group (median 7.9 mg/kg, Q1-Q3 0–12.8, p = 0.47). The median duration of gentamicin treatment was 3 days both in the study group and the control group (p = 0.58). Maximum predicted trough serum levels of gentamicin, cumulative area under the curve and gentamicin clearance were not different between cases and controls. The impact of gentamicin on SNHL can be minimized with treatments of short duration, monitoring of blood levels and dose adjustment.